Clinical Trial of YH32364 in Patients With Locally Advanced or Metastatic EGFR Overexpressing Solid Tumors

June 9, 2026 updated by: Yuhan Corporation

A Phase 1/2, Open-label, Multicenter, First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Anti-tumor Activity of YH32364 in Patients With Locally Advanced or Metastatic Solid Tumors

This is a study for people with locally advanced or metastatic cancer for whom previous treatment was not successful. Adults aged 18 and over with advanced cancer with Epidermal Growth Factor Receptor (EGFR) overexpressing can join the study. The purpose of this study is to find out whether a medicine called YH32364 helps people with locally advanced or metastatic cancers with EGFR overexpression.

Study Overview

Status

Recruiting

Conditions

Intervention / Treatment

Detailed Description

YH32364 is a new type of immunotherapy called a bispecific antibody that targets both Epidermal Growth Factor Receptor (EGFR) and 4-1BB. EGFR is a gene involved in cancer growth, and many cancer treatments aim to target it. 4-1BB, an immune-modulating protein, plays an important role in boosting T cell activity to combat cancer.

YH32364 is a treatment designed to activate 4-1BB specifically in tumors, aiming to avoid the liver-related side effects seen with previous 4-1BB treatments. It also helps block EGFR signals, assumed to make EGFR-targeted therapies more effective by overcoming resistance.

This study is consists of two parts. In Part 1, participants will be assigned sequentially to one of six dose levels, ranging from the lowest to the highest dose as determined by the sponsor, in order to identify an appropriate dosage.

In Part 2, participants will be randomly assigned to one of the two optimal dose levels identified in Part 1 to confirm the recommended dose.

The YH32364 will be administered via intravenous (IV) infusion once every two weeks. Participants will be required to visit the study site regularly for treatment and assessments. During all the visits, the doctors check participants' health and take note of any unwanted effects.

Study Type

Interventional

Enrollment (Estimated)

80

Phase

  • Phase 2
  • Phase 1

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact Backup

Study Locations

      • Seoul, South Korea, 03080
        • Recruiting
        • Seoul National University Hospital
      • Seoul, South Korea, 06351
        • Recruiting
        • Samsung Medical Center
      • Seoul, South Korea, 02841
        • Recruiting
        • Korea University Anam Hospital
      • Seoul, South Korea, 03722
        • Recruiting
        • Severance Hospital

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • Must sign an informed consent form (ICF) prior to any study specific procedures
  • ECOG performance status 0 or 1
  • Estimated life expectancy of at least 3 months
  • A woman must not be breastfeeding
  • Have at least one measurable lesion, not previously irradiated and not chosen for biopsy during the study screening period, that can be accurately measured at baseline ≥10 mm in the longest diameter (except lymph nodes which must have a short axis of ≥15 mm) with computerized tomography (CT) or magnetic resonance imaging (MRI), are suitable for accurate repeated measurements.

[Dose Escalation Only] Locally advanced or metastatic EGFR overexpressing solid tumor* that is refractory or intolerable on all available standard therapy and that is considered uncurable by local therapy

* One of the following pathologically confirmed EGFR overexpressing (IHC3+ or IHC2+) tumors.

  • Head and neck squamous cell carcinoma (HNSCC)
  • Non-small cell lung cancer (NSCLC): squamous cell carcinoma (SqCC)
  • Esophageal squamous cell carcinoma (ESCC)
  • Biliary tract cancer (BTC)
  • Uterine cervical cancer
  • Vulvar cancer
  • Urothelial cancer
  • Squamous cell carcinoma of other origin of tumor (e.g., skin squamous cell tumor)

[Dose Expansion Only] Cohort 1: Pathologically confirmed EGFR overexpressing (IHC3+ or IHC2+), locally advanced or metastatic HNSCC other than nasopharyngeal carcinoma (NPC)* that is refractory or intolerable on all available standard therapy and that is considered uncurable by local therapy.

Exclusion Criteria:

  • Known uncontrolled central nervous system (CNS) metastases, spinal cord compression, and/or carcinomatous meningitis
  • Have history of a second primary cancer with the exception of

    • curatively treated non-melanomatous skin cancer
    • curatively treated cervical or breast carcinoma in situ, or
    • other malignancy with no known active disease present and no treatment administered during the last 2 years
  • Have history of or current Class II, III or IV heart failure as defined by the New York Heart Association (NYHA)
  • Have history of acute coronary syndromes, including myocardial infarction, coronary artery bypass graft, unstable angina, coronary angioplasty or stenting within past 24 weeks
  • Have history of (non-infectious) interstitial lung disease (ILD) or pneumonitis that required steroids, or any evidence of current ILD or pneumonitis
  • Have autoimmune disease that has required systemic treatment
  • Infection with human immunodeficiency virus (HIV)
  • Active chronic hepatitis B or chronic hepatitis C

[Prior/Concomitant Therapy]

  • Have received systemic steroid therapy
  • Previous treatment with a 4-1BB/CD137-modulating agent
  • Have used a live vaccine within 4 weeks
  • Have received treatment with immunotherapy, biological therapies, targeted small molecules, or hormonal therapies
  • Have received radiation therapy
  • Have received cytotoxic chemotherapy

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: N/A
  • Interventional Model: Single Group Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: YH32364

Dose Escalation Part: Dose Escalation part is designed to assess the safety and tolerability of YH32364 and to identify the Maximum Tolerated dose (MTD) and/or two dose levels for recommended dose (RD) selection.

Dose Expansion Part: Dose Expansion part will consist of multiple cohorts by cancer types. Cohort 1 will be initiated to determine the RD after completion of Part 1. The RD will be determined among two dose levels investigated in Cohort 1 based on the totality of available data including PK, biomarkers, dose-response, safety, and efficacy.

Dose Escalation Part: In this part, 6 dose levels are planned and approximately 30 patients will be enrolled. After each dose level, Safety Review Committee (SRC) will evaluate the available safety, tolerability, PK of YH32364 to decide the next dose.

Dose Expansion Part: 50 participants with previously treated locally advanced or metastatic EGFR overexpressing HNSCC other than NPC will be randomized 1:1 ratio to each dose. (Cohort 1: Participants with locally advanced or metastatic EGFR overexpressing HNSCC other than NPC, whose disease progressed after or who are intolerable to all the available standard treatment)

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Treatment-emergent adverse events (TEAEs) including dose limiting toxicities (DLTs)
Time Frame: Study Day 1 to Study Day 28 (during the DLTs evaluation period)
To assess the safety and tolerability of YH32364 in order to determine maximum tolerated dose (MTD) and select doses for dose optimization
Study Day 1 to Study Day 28 (during the DLTs evaluation period)
Objective Response Rate (ORR)
Time Frame: through dose expansion part completion, approximately 1.5 year
To assess the ORR of YH32364 at the recommended dose (RD) according to RECIST v1.1 by Investigator assessment
through dose expansion part completion, approximately 1.5 year

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Area under the serum concentration-time curve from time 0 to the last quantifiable concentration (AUClast)
Time Frame: through study completion, approximately 2.5 year
To characterize the pharmacokinetics (PK) of YH32364
through study completion, approximately 2.5 year
AUC from time 0 to infinity (AUCinf)
Time Frame: through study completion, approximately 2.5 year
To characterize the pharmacokinetics (PK) of YH32364
through study completion, approximately 2.5 year
Maximum observed serum concentration (Cmax)
Time Frame: through study completion, approximately 2.5 year
To characterize the pharmacokinetics (PK) of YH32364
through study completion, approximately 2.5 year
Time to reach Cmax (Tmax)
Time Frame: through study completion, approximately 2.5 year
To characterize the pharmacokinetics (PK) of YH32364
through study completion, approximately 2.5 year
Apparent terminal elimination half-life (t1/2)
Time Frame: through study completion, approximately 2.5 year
To characterize the pharmacokinetics (PK) of YH32364
through study completion, approximately 2.5 year
Total clearance (CL)
Time Frame: through study completion, approximately 2.5 year
To characterize the pharmacokinetics (PK) of YH32364
through study completion, approximately 2.5 year
Volume of distribution (Vd)
Time Frame: through study completion, approximately 2.5 year
To characterize the pharmacokinetics (PK) of YH32364
through study completion, approximately 2.5 year
Volume of distribution at steady state (Vss)
Time Frame: through study completion, approximately 2.5 year
To characterize the pharmacokinetics (PK) of YH32364
through study completion, approximately 2.5 year
AUC during dosing interval at steady state (AUCtau)
Time Frame: through study completion, approximately 2.5 year
To characterize the pharmacokinetics (PK) of YH32364
through study completion, approximately 2.5 year
Cmax at steady state (Cmax,ss)
Time Frame: through study completion, approximately 2.5 year
To characterize the pharmacokinetics (PK) of YH32364
through study completion, approximately 2.5 year
Time to reach Cmax,ss (Tmax,ss)
Time Frame: through study completion, approximately 2.5 year
To characterize the pharmacokinetics (PK) of YH32364
through study completion, approximately 2.5 year
Accumulation ratio (Rac)
Time Frame: through study completion, approximately 2.5 year
To characterize the pharmacokinetics (PK) of YH32364
through study completion, approximately 2.5 year
Trough (predose) serum concentration on Cycle 4 (Ctrough)
Time Frame: through study completion, approximately 2.5 year
To characterize the pharmacokinetics (PK) of YH32364
through study completion, approximately 2.5 year
Presence and characterization of YH32364 ADA including neutralizing antibodies
Time Frame: through study completion, approximately 2.5 year
To explore the immunogenicity of YH32364
through study completion, approximately 2.5 year
Titer of YH32364 ADA
Time Frame: through study completion, approximately 2.5 year
To explore the immunogenicity of YH32364
through study completion, approximately 2.5 year
Objective Response Rate (ORR)
Time Frame: through dose escalation part completion, approximately 1 year
To assess the anti-tumor activity according to RECIST v1.1 by Investigator assessment
through dose escalation part completion, approximately 1 year
Duration of Response (DoR)
Time Frame: through study completion, approximately 2.5 year
To assess the anti-tumor activity according to RECIST v1.1 by Investigator assessment
through study completion, approximately 2.5 year
Disease Control Rate (DCR)
Time Frame: through study completion, approximately 2.5 year
To assess the anti-tumor activity according to RECIST v1.1 by Investigator assessment
through study completion, approximately 2.5 year
Depth of Response
Time Frame: through study completion, approximately 2.5 year
To assess the anti-tumor activity according to RECIST v1.1 by Investigator assessment
through study completion, approximately 2.5 year
Time to Response
Time Frame: through study completion, approximately 2.5 year
To assess the anti-tumor activity according to RECIST v1.1 by Investigator assessment
through study completion, approximately 2.5 year
Progression-free survival (PFS)
Time Frame: through study completion, approximately 2.5 year
To assess the anti-tumor activity according to RECIST v1.1 by Investigator assessment
through study completion, approximately 2.5 year
TEAEs
Time Frame: through dose expansion part completion, approximately 1.5 year
To assess the safety and tolerability of YH32364
through dose expansion part completion, approximately 1.5 year
Overall Survival (OS)
Time Frame: through dose expansion part completion, approximately 1.5 year
To assess the overall survival of YH32364 at the RD
through dose expansion part completion, approximately 1.5 year

Other Outcome Measures

Outcome Measure
Measure Description
Time Frame
Immune ORR (iORR)
Time Frame: through study completion, approximately 2.5 year
To assess the immune-related efficacy according to iRECIST by Investigator assessment
through study completion, approximately 2.5 year
Immune Duration of Response (iDOR)
Time Frame: through study completion, approximately 2.5 year
To assess the immune-related efficacy according to iRECIST by Investigator assessment
through study completion, approximately 2.5 year
Immune PFS (iPFS)
Time Frame: through study completion, approximately 2.5 year
To assess the immune-related efficacy according to iRECIST by Investigator assessment
through study completion, approximately 2.5 year

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Investigators

  • Study Director: Yuhan Clinical Research Physician, Yuhan Corporation

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

June 12, 2025

Primary Completion (Estimated)

June 1, 2027

Study Completion (Estimated)

December 1, 2029

Study Registration Dates

First Submitted

April 28, 2025

First Submitted That Met QC Criteria

May 7, 2025

First Posted (Actual)

May 16, 2025

Study Record Updates

Last Update Posted (Actual)

June 10, 2026

Last Update Submitted That Met QC Criteria

June 9, 2026

Last Verified

June 1, 2026

More Information

Terms related to this study

Other Study ID Numbers

  • YH32364-101

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

YES

IPD Plan Description

De-identified individual participant data (including data dictionaries) that underline the results reported in study-related publications will be made available during the period beginning 1 year and ending 5 years after all trial primary and secondary endpoints were assessed. Only requests from researchers who provide a methodologically sound proposal will be reviewed and approved by the sponsor. The analysis type should be in accordance with aims in the proposal approved by the sponsor. Proposals should be directed to clinicaltrials@yuhan.co.kr

A summary of the study results will be posted in the publicly accessible database (i.e. clinicaltrials.gov) no later than 1 year after the study's primary completion date.

IPD Sharing Time Frame

Beginning 1 year and ending 5 years after all trial endpoints were assessed

IPD Sharing Access Criteria

Only requests from researchers who provide a methodologically sound proposal will be reviewed and approved by the sponsor. The analysis type should be in accordance with aims in the proposal approved by the sponsor. Proposals should be directed to clinicaltrials@yuhan.co.kr

IPD Sharing Supporting Information Type

  • STUDY_PROTOCOL
  • SAP
  • CSR

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.